lutetium

Summary

Summary: An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.

Top Publications

  1. Lantry L, Cappelletti E, Maddalena M, Fox J, Feng W, Chen J, et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144-52 pubmed
    ..We describe a new radiolabeled bombesin (BBN) analog for imaging and systemic radiotherapy that has improved pharmacokinetics (PK) and better retention of radioactivity in the tumor...
  2. De Jong M, Breeman W, Bernard B, Bakker W, Schaar M, van Gameren A, et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628-33 pubmed
    ..This candidate molecule shows great promise for radionuclide therapy in patients with sst(2)-expressing tumors...
  3. Sierra M, Agazzi A, Bodei L, Pacifici M, Aricò D, De Cicco C, et al. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother Radiopharm. 2009;24:659-65 pubmed publisher
    ..Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT...
  4. Stickel J, Qi J, Cherry S. Fabrication and characterization of a 0.5-mm lutetium oxyorthosilicate detector array for high-resolution PET applications. J Nucl Med. 2007;48:115-21 pubmed
    ..Though there are other contributing factors, the spatial resolution in small-animal PET is still largely determined by the detector pixel dimensions...
  5. Vallabhajosula S, Goldsmith S, Hamacher K, Kostakoglu L, Konishi S, Milowski M, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850-8 pubmed
  6. de Jong M, Breeman W, Valkema R, Bernard B, Krenning E. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:13S-7S pubmed
    ..Suitable radionuclides are (90)Y, a pure, high-energy beta-emitter (2.27 MeV), and (177)Lu, a medium-energy beta-emitter (0.5 MeV) with a low-abundance gamma...
  7. Pichler B, Swann B, Rochelle J, Nutt R, Cherry S, Siegel S. Lutetium oxyorthosilicate block detector readout by avalanche photodiode arrays for high resolution animal PET. Phys Med Biol. 2004;49:4305-19 pubmed
    ..The readout of densely packed, 10 x 10 lutetium oxyorthosilicate (LSO) block detectors (crystal size 2.0 x 2...
  8. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi J, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-15 pubmed
    ..The aim of this study was to develop radiolabeled (Indium-111, Lutetium-177, and Yttrium-90) bombesin analogues with affinity to the three bombesin receptor subtypes for targeted ..
  9. Forrer F, Riedweg I, Maecke H, Mueller Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52:334-40 pubmed
    ..We evaluated the effectiveness and toxicity of radiolabeled DOTATOC in patients with metastatic paraganglioma and pheochromocytoma...

More Information

Publications62

  1. Stillebroer A, Zegers C, Boerman O, Oosterwijk E, Mulders P, O Donoghue J, et al. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med. 2012;53:82-9 pubmed publisher
    ..The estimated radiation doses were correlated with observed hematologic toxicity. In addition, the accuracy of the predicted therapeutic absorbed doses, based on diagnostic (111)In-cG250 data, were determined...
  2. Girard E, Anelli P, Vicat J, Kahn R. High-phasing-power lanthanide derivatives: taking advantage of ytterbium and lutetium for optimized anomalous diffraction experiments using synchrotron radiation. Acta Crystallogr D Biol Crystallogr. 2003;59:1877-80 pubmed
    Ytterbium and lutetium are well suited for optimized anomalous diffraction experiments using synchrotron radiation...
  3. Kunikowska J, Krolicki L, Hubalewska Dydejczyk A, Mikołajczak R, Sowa Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?. Eur J Nucl Med Mol Imaging. 2011;38:1788-97 pubmed publisher
    ..The aim of the study was to evaluate combined 90Y/177Lu-DOTATATE therapy in comparison to 90Y-DOTATATE alone...
  4. Garkavij M, Nickel M, Sjögreen Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084-92 pubmed publisher
    ..In commonly used dosimetry methods, planar imaging is used for determination of the residence time, whereas the kidney mass is determined from a computed tomography (CT) scan...
  5. Pach D, Sowa Staszczak A, Kunikowska J, Krolicki L, Trofimiuk M, Stefańska A, et al. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiother Oncol. 2012;102:45-50 pubmed publisher
    ..PRRT is a known tool in the management of patients with disseminated and inoperable NETs. The aim of study was to assess the effectiveness of the repeated cycles of PRRT in patients with disseminated and inoperable NETs...
  6. Kam B, Teunissen J, Krenning E, de Herder W, Khan S, van Vliet E, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S103-12 pubmed publisher
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours. ..
  7. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller Brand J, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140:968-76; discussion 976-7 pubmed
    ..The aim of the study was to present clinical experience with (90)Y- and (177)Lu-DOTATOC therapy in the management of NET...
  8. Zhu X, Zhou J, Chen M, Shi M, Feng W, Li F. Core-shell Fe3O4@NaLuF4:Yb,Er/Tm nanostructure for MRI, CT and upconversion luminescence tri-modality imaging. Biomaterials. 2012;33:4618-27 pubmed publisher
    ..In vitro tests reveal that the MUCNP is non-cytotoxic. These results suggest that the developed MUCNP could be served as an MR, CT and UCL probe for tri-modality imaging...
  9. Wehrmann C, Senftleben S, Zachert C, Müller D, Baum R. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22:406-16 pubmed
    ..In this study, we compared the dosimetric parameter uptake, half-life (kinetics), and mean absorbed organ and tumor doses of (177)Lu DOTA-NOC and (177)Lu DOTA-TATE...
  10. Kwekkeboom D, Bakker W, Kooij P, Konijnenberg M, Srinivasan A, Erion J, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28:1319-25 pubmed
    ..Also, labelled with the beta- and gamma-emitting radionuclide lutetium-177, this compound has been shown to have a very favourable impact on tumour regression and animal survival in a ..
  11. de Keizer B, van Aken M, Feelders R, de Herder W, Kam B, van Essen M, et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008;35:749-55 pubmed publisher
    ..The aim of this study was to investigate the incidence of hormonal crises after therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate)...
  12. Rappel C, Schaumlöffel D. Absolute peptide quantification by lutetium labeling and nanoHPLC-ICPMS with isotope dilution analysis. Anal Chem. 2009;81:385-93 pubmed publisher
    ..work, a novel approach was developed for accurate absolute peptide quantification based on metal labeling with lutetium diethylenetriamine pentaacetic acid (Lu-DTPA) and nanoflow high-performance liquid chromatography-inductively ..
  13. Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med. 2005;46:2083-91 pubmed
    This article reports the results of performance measurements obtained for the lutetium oxyorthosilicate (LSO)-based whole-body PET/CT scanner Biograph 16 HI-REZ with the National Electrical Manufacturers Association (NEMA) NU 2-2001 ..
  14. Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Schmitt J, et al. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm. 2003;18:593-9 pubmed
    ..In this study the biodistribution of a somatostatin analogue, (177)Lu-[DOTA(0),Tyr(3)]octreotate, was investigated in an animal model, as a possible therapeutic radiopharmaceutical...
  15. Breeman W, Mearadji A, Capello A, Bernard B, van Eijck C, Krenning E, et al. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model. Int J Cancer. 2003;104:376-9 pubmed
    ..177)Lu-DOTA-tate showed anti-tumoral effects in both cases and significant survival in the PRRT-treated rats. (177)Lu-DOTA-tate is a very promising new treatment modality for SSR-positive tumors, including disseminated disease...
  16. Teunissen J, Kwekkeboom D, Krenning E. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004;22:2724-9 pubmed
    ..To evaluate the quality of life (QoL) in patients with metastatic somatostatin receptor positive gastroenteropancreatic tumors treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) therapy...
  17. De Decker M, Turner J. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2012;27:72-6 pubmed publisher
  18. Salavati A, Prasad V, Schneider C, Herbst R, Baum R. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med. 2012;26:365-9 pubmed publisher
  19. Halpern B, Dahlbom M, Auerbach M, Schiepers C, Fueger B, Weber W, et al. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med. 2005;46:603-7 pubmed
    High photon attenuation and scatter in obese patients affect image quality. The purpose of the current study was to optimize lutetium orthosilicate (LSO) PET image acquisition protocols in patients weighing > or =91 kg (200 lb).
  20. Apetrei C, Alessio P, Constantino C, de Saja J, Rodriguez Mendez M, Pavinatto F, et al. Biomimetic biosensor based on lipidic layers containing tyrosinase and lutetium bisphthalocyanine for the detection of antioxidants. Biosens Bioelectron. 2011;26:2513-9 pubmed publisher
    ..preparation of a biomimetic Langmuir-Blodgett film of tyrosinase incorporated in a lipidic layer and the use of lutetium bisphthalocyanine as an electron mediator for the voltammetric detection of phenol derivatives, which include one ..
  21. Yang Y, Sun Y, Cao T, Peng J, Liu Y, Wu Y, et al. Hydrothermal synthesis of NaLuF4:153Sm,Yb,Tm nanoparticles and their application in dual-modality upconversion luminescence and SPECT bioimaging. Biomaterials. 2013;34:774-83 pubmed publisher
    ..It also introduces an easy methodology to quantify in vivo biodistribution of nanomaterials which still needs further understanding as a community...
  22. Barber T, Hofman M, Thomson B, Hicks R. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38:64-71 pubmed publisher
  23. Capello A, Krenning E, Breeman W, Bernard B, Konijnenberg M, de Jong M. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm. 2003;18:761-8 pubmed
    ..In conclusion, tyr3-octreotate labeled with 177Lu or 90Y is the most promising analog for PRRT...
  24. Breeman W, van der Wansem K, Bernard B, van Gameren A, Erion J, Visser T, et al. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30:312-5 pubmed
    ..After labelling [DOTA(0),Tyr(3)]octreotate with (177)Lu the addition of DTPA prior to intravenous administration of [(177)Lu-DOTA(0),Tyr(3)]octreotate is strongly recommended...
  25. Swärd C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, et al. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm. 2008;23:114-20 pubmed publisher
    ..Octreotate seems to be a more suitable somatostatin analog than octreotide for receptor-mediated radiation therapy. P-CgA is a simple, accurate method for the estimation of tumor response in this animal model...
  26. Dvorakova Z, Henkelmann R, Lin X, Turler A, Gerstenberg H. Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu. Appl Radiat Isot. 2008;66:147-51 pubmed
    ..The comparison of theoretically calculated and experimentally determined yield for Lu176(n,gamma)Lu177 reaction is presented...
  27. Miller W, Hartmann Siantar C, Fisher D, Descalle M, Daly T, Lehmann J, et al. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother Radiopharm. 2005;20:436-49 pubmed
  28. Fearon W, Ikeno F, Bailey L, Hiatt B, Herity N, Carter A, et al. Evaluation of high-pressure retrograde coronary venous delivery of FGF-2 protein. Catheter Cardiovasc Interv. 2004;61:422-8 pubmed
    ..30-1.23; P < 0.05), but did not change significantly in the other three arms. High-pressure retrograde injection into the AIV may represent an efficient and effective means for delivering angiogenic factors to ischemic myocardium...
  29. Jordan D, Malin J, Geiger F. Interactions of Al(III), La(III), Gd(III), and Lu(III) with the fused silica/water interface studied by second harmonic generation. Environ Sci Technol. 2010;44:5862-7 pubmed publisher
    ..The thermodynamic results from this work are valuable benchmarks for computer simulations of trivalent metal transport in the environment...
  30. Erdi Y, Nehmeh S, Mulnix T, Humm J, Watson C. PET performance measurements for an LSO-based combined PET/CT scanner using the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med. 2004;45:813-21 pubmed
    Results of performance measurements for a lutetium oxyorthosilicate (LSO)-based PET/CT scanner using new National Electrical Manufacturers Association (NEMA) NU 2-2001 standards are reported.
  31. Miao Y, Shelton T, Quinn T. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm. 2007;22:333-41 pubmed
    ..The aim of this study was to examine the therapeutic efficacy of (177)Lu-DOTA-Re(Arg(11))CCMSH in the B16/F1 murine melanoma-bearing mouse model...
  32. Baum R, Kluge A, Kulkarni H, Schorr Neufing U, Niepsch K, Bitterlich N, et al. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics. 2016;6:501-10 pubmed publisher
    ..To characterise efficacy and safety of (177)Lu-DOTATOC as agent for peptide receptor radiotherapy (PRRT) of advanced neuroendocrine tumours (NET)...
  33. Parus J, Mikolajczak R. Beta-emitting radionuclides for peptide receptor radionuclide therapy. Curr Top Med Chem. 2012;12:2686-93 pubmed
    ..These promising results together with the increasing availability of other ?-emitting radionuclides are a good basis for further studies. ..
  34. Reismann P, Kender Z, Dabasi G, Sréter L, Racz K, Igaz P. [Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients]. Orv Hetil. 2011;152:392-7 pubmed publisher
    ..used radionuclides for neuroendocrine tumor treatment are the ?-emitter Yttrium-90 (??Y) and the ?+? emitter Lutetium-177 (¹??Lu)...
  35. Shcherbinin S, Piwowarska Bilska H, Celler A, Birkenfeld B. Quantitative SPECT/CT reconstruction for ¹??Lu and ¹??Lu/??Y targeted radionuclide therapies. Phys Med Biol. 2012;57:5733-47 pubmed publisher
    ..Our analysis of patient study demonstrated that lack of corrections led to overestimation of activities in organs and tumor by 29-39% for the diagnostic scan with (99m)Tc and by 105-218% for post-therapy scan with ¹??Lu...
  36. Forrer F, Oechslin Oberholzer C, Campana B, Maecke H, Mueller Brand J, Lohri A. Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. Q J Nucl Med Mol Imaging. 2012;56:544-50 pubmed
  37. Eriksson S, Ohlsson T, Nilsson R, Tennvall J. Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model. Cancer Biother Radiopharm. 2012;27:175-82 pubmed publisher
    ..with syngeneic grafted colon carcinomas were administered the minimal effective therapeutic dose of 400 MBq/kg lutetium-177 ((177)Lu)-DOTA-BR96...
  38. Fathi M, Taghikhani M, Ghannadi Maragheh M, Yavari K. Demonstration of dose dependent cytotoxic activity in SW480 colon cancer cells by ¹??Lu-labeled siRNA targeting IGF-1R. Nucl Med Biol. 2013;40:529-36 pubmed publisher
    ..In this study, radioconjugate of IGF-1R siRNA with lutetium-177 ((177)Lu) was produced, and the anti-proliferation and apoptosis effects elicited by this (177)Lu-siRNA ..
  39. Abbasi I. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation. Nucl Med Biol. 2011;38:417-25 pubmed publisher
    ..Based on these facts, it was hypothesized that a bone-seeking (177)Lu-MDP (lutetium-177-labeled MDP) radiopharmaceutical could be developed as an agent for palliative radiotherapy of bone pain due ..
  40. Krenning E, Teunissen J, Valkema R, deHerder W, deJong M, Kwekkeboom D. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. J Endocrinol Invest. 2005;28:146-50 pubmed
    ..Also, the development of therapy strategies with combinations of different radionuclides and or peptides is of interest as these strategies may provide an increase in therapeutic efficacy in the future...
  41. Lewis M, Zhang J, Jia F, Owen N, Cutler C, Embree M, et al. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol. 2004;31:213-23 pubmed
    ..2% ID/g), and (177)Lu (35.4% ID/g) peaked at 1-4 h. Rapid blood disappearance was accompanied by urinary excretion of 59-66% ID within 1 h. Biodistributions of these agents show promise for pretargeted radioimmunotherapy of cancer...
  42. Galunin E, Alba M, Avilés M, Santos M, Vidal M. Reversibility of La and Lu sorption onto smectites: implications for the design of engineered barriers in deep geological repositories. J Hazard Mater. 2009;172:1198-205 pubmed publisher
    ..Based on all the data, SCa-3, HEC and FEBEX clays are considered the best choices for water environments, whereas in Ca environments the suitable clays depended on the lanthanide considered...
  43. Lee S, Hong Y, Pyun M, Felipe P, Choi S. Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with (177)Lu for potential use in radioimmunotherapy. Appl Radiat Isot. 2009;67:1185-9 pubmed publisher
    ..This radioimmunoconjugate is applicable to detect of angiogenesis sites in various diseases and treat tumors overexpressing VEGFR 1...
  44. Buchsbaum D, Khazaeli M, Axworthy D, Schultz J, Chaudhuri T, Zinn K, et al. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clin Cancer Res. 2005;11:8180-5 pubmed
    ..This study examined a pretarget radioimmunotherapy strategy for treatment of an i.p. tumor model (LS174T)...
  45. Balkin E, Jia F, Miller W, Lewis M. In vitro evaluation of targeted antisense 177Lu radiotherapy. Anticancer Res. 2011;31:3143-9 pubmed
    ..e., simultaneous down-regulation of BCL2-mediated resistance to apoptosis and delivery of cytotoxic internally emitted radiation...
  46. Vera D, Eigner S, Henke K, Lebeda O, Melichar F, Beran M. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl Med Biol. 2012;39:3-13 pubmed publisher
    ..The aim of this work was to evaluate the conjugate (177)Lu-h-R3 as a potential radioimmunoconjugate for radioimmunotherapy (RIT) of tumors overexpressing EGFR...
  47. Bernhardt P, Ahlman H, Forssell Aronsson E. Model of metastatic growth valuable for radionuclide therapy. Med Phys. 2003;30:3227-32 pubmed
    ..However, the short half-life of 103mRh (56 min) might not be optimal for therapy. Therefore, other low-energy electron emitters, or alpha emitters, should be considered for systemic targeted therapy...
  48. Jia G, You H, Song Y, Jia J, Zheng Y, Zhang L, et al. Facile chemical conversion synthesis and luminescence properties of uniform Ln3+ (Ln = Eu, Tb)-doped NaLuF4 nanowires and LuBO3 microdisks. Inorg Chem. 2009;48:10193-201 pubmed publisher
    ..The lutetium precursor nanowires were first prepared through a simple hydrothermal process...
  49. Orcutt K, Rhoden J, Ruiz Yi B, Frangioni J, Wittrup K. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther. 2012;11:1365-72 pubmed publisher
    ..We use relations derived from the model to develop design criteria for the future development of small-molecule agents for targeted cancer therapeutics...
  50. Wang X, Fani M, Schulz S, Rivier J, Reubi J, Maecke H. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:1876-85 pubmed publisher
    ..The present report describes the evaluation of this novel antagonist labelled with (111)In and (177)Lu in three different tumour models...
  51. de Jong G, Boerman O, Heskamp S, Aarts F, Bleichrodt R, Hendriks T. Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model. Br J Surg. 2009;96:314-21 pubmed publisher
    ..Radioimmunotherapy (RIT) is suitable for the treatment of microscopic residual disease and might therefore have an adjuvant role after colonic cancer surgery...
  52. Hens M, Vaidyanathan G, Welsh P, Zalutsky M. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol. 2009;36:117-28 pubmed publisher
  53. van Essen M, Krenning E, Kooij P, Bakker W, Feelders R, de Herder W, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599-606 pubmed
    ..Here we present the effects of this therapy in a small number of patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs), and melanomas...